Does a surgeon’s complication rate in a randomized controlled trial constitute a “significant new finding” that must be reported to patients during the consent process?
A clinical case shows how medical commercialism poses risks to patients without symptoms who get full body scans. Screening for pre-morbid disease detection is valuable if implemented correctly but calls for physician caution.
Explanation of the Medicare and Medicaid Antikickback statute and Stark Law and their restrictions on physicians' financial interests in ancillary services.
Physicians’ ethical obligations to disclose conflicts of interest to patients and to obtain their informed consent for treatment are particularly critical when proposed treatments are experimental.